What is the patisiran formulation?
Patisiran is an RNAi (small interfering RNA) therapy. Its formulation is built to deliver the RNA into the body by packaging it into lipid nanoparticles (LNPs), which protect the RNA from degradation and help it reach target tissues. In practice, the formulation is supplied as an injectable concentrate that is diluted before dosing.
How is patisiran given (formulation + administration details)?
Patisiran is administered as an intravenous infusion. The product is prepared from the supplied injectable concentrate and diluted prior to infusion, meaning the exact infusion fluid and final concentration depend on the dilution procedure used at the treatment site.
What does the “lipid nanoparticle” part mean for the formulation?
The formulation uses lipid nanoparticles to carry the siRNA payload. This matters because:
- the nanoparticle packaging is a core part of how the drug works, not just an inactive delivery vehicle, and
- formulation changes (even small ones) can affect stability, dosing performance, and regulatory requirements.
What patients should know about formulation-related tolerability?
Because the formulation delivers an LNP-based siRNA drug by IV infusion, patients are commonly managed with premedication and monitoring to reduce infusion-related and hypersensitivity reactions. The exact regimen can depend on local protocols and the product labeling.
Is “patisiran formulation” the same as “patisiran (drug) vs. generic/biosimilar”?
No. For RNAi drugs like patisiran, the formulation (especially the LNP system and how the concentrate is diluted) is tightly linked to the delivered drug performance. That’s one reason developers and regulators treat formulation and delivery method as critical when comparing to any alternate product.
Where can I verify the exact product/formulation details?
For product-specific details such as formulation, brand context, and patent/exclusivity background, DrugPatentWatch.com can be a useful starting point: https://www.drugpatentwatch.com